miR-615-5p expression was also markedly lower than normal cells and tissue in prostatic adenocarcinoma, in which CCND2 mRNA (cyclin D2) was upregulated in the absence of the inhibitory effect of miR-615-5p, promoting cell cycle progression [62]. This evidence concerns the gene CCND2 and prostate adenocarcinoma.